These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7771262)

  • 1. The potential of gliclazide, a sulphonylurea to influence the oxidative processes within the pathogenesis of diabetic vascular disease.
    Jennings PE
    Adv Exp Med Biol; 1994; 366():313-24. PubMed ID: 7771262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From hemobiology to vascular disease: a review of the potential of gliclazide to influence the pathogenesis of diabetic vascular disease.
    Jennings PE
    J Diabetes Complications; 1994; 8(4):226-30. PubMed ID: 7833498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular benefits of gliclazide beyond glycemic control.
    Jennings PE
    Metabolism; 2000 Oct; 49(10 Suppl 2):17-20. PubMed ID: 11078471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Free radical scavenging activity of sulfonylureas: a clinical assessment of the effectiveness of gliclazide].
    Jennings PE; Belch JJ
    Ter Arkh; 2001; 73(4):27-31. PubMed ID: 11494442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of gliclazide on thromboxane B2, parameters of haemostasis, fluorescent IgG and lipid peroxides in non-insulin dependent diabetes mellitus.
    Florkowski CM; Richardson MR; Le Guen C; Jennings PE; O'Donnell MJ; Jones AF; Lunec J; Barnett AH
    Diabetes Res; 1988 Oct; 9(2):87-90. PubMed ID: 3149923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic endothelial dysfunction: effect of free radical scavenging in Type 2 diabetic patients.
    De Mattia G; Laurenti O; Fava D
    J Diabetes Complications; 2003; 17(2 Suppl):30-5. PubMed ID: 12623166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship of oxidative stress to thrombotic tendency in type 1 diabetic patients with retinopathy.
    Jennings PE; McLaren M; Scott NA; Saniabadi AR; Belch JJ
    Diabet Med; 1991 Nov; 8(9):860-5. PubMed ID: 1837513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monocyte adhesion in diabetic angiopathy: effects of free-radical scavenging.
    Renier G; Mamputu JC; Desfaits AC; Serri O
    J Diabetes Complications; 2003; 17(2 Suppl):20-9. PubMed ID: 12623165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo antioxidant properties of gliclazide.
    O'Brien RC; Luo M; Balazs N; Mercuri J
    J Diabetes Complications; 2000; 14(4):201-6. PubMed ID: 11004429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide.
    Jennings PE; Belch JJ
    Metabolism; 2000 Feb; 49(2 Suppl 1):23-6. PubMed ID: 10693916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of gliclazide and glibenclamide on platelet function, fibrinolysis and metabolic control in diabetic patients with retinopathy (author's transl)].
    Chan TK; Chan V; Teng CS; Yeung RT
    Sem Hop; 1982 May; 58(19):1197-200. PubMed ID: 6285503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: clinical assessment.
    Jennings PE; Scott NA; Saniabadi AR; Belch JJ
    Metabolism; 1992 May; 41(5 Suppl 1):36-9. PubMed ID: 1574014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical scavenging effect of gliclazide in diabetic rats fed with a high cholesterol diet.
    Onozato ML; Tojo A; Goto A; Fujita T
    Kidney Int; 2004 Mar; 65(3):951-60. PubMed ID: 14871415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
    Konya H; Hasegawa Y; Hamaguchi T; Satani K; Umehara A; Katsuno T; Ishikawa T; Miuchi M; Kohri K; Suehiro A; Kakishita E; Miyagawa J; Namba M
    Metabolism; 2010 Sep; 59(9):1294-9. PubMed ID: 20070990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study.
    Larkins RG; Jerums G; Taft JL; Godfrey H; Smith IL; Martin TJ
    Diabetes Res Clin Pract; 1988 Jan; 4(2):81-7. PubMed ID: 3125029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic retinopathy in non-insulin-dependent diabetes mellitus patients: the role of gliclazide.
    Akanuma Y; Kosaka K; Kanazawa Y; Kasuga M; Fukuda M; Aoki S
    Am J Med; 1991 Jun; 90(6A):74S-76S. PubMed ID: 1872308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes.
    Fava D; Cassone-Faldetta M; Laurenti O; De Luca O; Ghiselli A; De Mattia G
    Diabet Med; 2002 Sep; 19(9):752-7. PubMed ID: 12207812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of secondary failure rate between three second generation sulphonylureas.
    Harrower AD; Wong C
    Diabetes Res; 1990 Jan; 13(1):19-21. PubMed ID: 2129025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.
    Holmes B; Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1984 Apr; 27(4):301-27. PubMed ID: 6373223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gliclazide: review of metabolic and vascular action].
    Alberti KG
    Diabete Metab; 1994 Nov; 20(3 Pt 2):341-8. PubMed ID: 7828778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.